-market-report.png)
Acute Kidney Injury Market
- Currently, there are no targeted pharmacotherapies approved for the Acute Kidney Injury treatment. At present, the Acute Kidney Injury Therapeutic Market Size is mainly dominated by the use of RRT and off-label drugs, which include various classes such as ACE inhibitors, ARBs, Diuretics, and NSAIDs.
- The Acute Kidney Injury Incidence is on the rise, particularly in individuals with acute illnesses and potentially those undergoing significant surgical procedures.
- Total mortality-adjusted incident cases of Acute Kidney Injury in hospitalized patients in the 7MM accounted for approximately 14.6 million in 2022.
- In 2022, the Acute Kidney Injury Market Size was highest in the United States among the 7MM, accounting for approximately 65%, which is further expected to increase by 2034.
- In December 2023, SeaStar Medical announced enrollment of patients in the NEUTRALIZE-Acute Kidney Injury clinical trials of its cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill adults with Acute Kidney Injury requiring continuous kidney replacement therapy (CKRT).
- In October 2023, Renibus Therapeutics announced that the first patient had been dosed in the pivotal Phase III PROTECT trial of RBT-1 for patients with post-operative complications in cardiac surgery. Top-line results are expected in mid-2025. NDA filing is anticipated by early 2026.
Request a sample to unlock the CAGR for Acute Kidney Injury Treatment Market
.jpg)
DelveInsight's "Acute Kidney Injury Market Insights, Epidemiology and Market Forecast–2034” report delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Acute Kidney Injury Therapeutics Market Report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Kidney Injury market size from 2020 to 2034. The report also covers current Acute Kidney Injury treatment market practices/algorithms, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Kidney Injury drugs market.
| Study Period | 2020 to 2034 |
| Forecast Period | 2024-2034 |
| Geographies Covered |
|
| Acute Kidney Injury Market |
|
| Acute Kidney Injury Market Size | USD 6230 Million in 2023 |
| Acute Kidney Injury Companies |
|
Acute Kidney Injury Treatment Market
Acute Kidney Injury is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over hours to weeks. Signs and symptoms of Acute Kidney Injury include nausea, vomiting, weakness, dizziness, and, pain in the lower back. Some patients are asymptomatic (no noticeable symptoms) and others may have generalized non-specific (not specific to kidneys) symptoms.
Acute Kidney Injury Diagnosis
The history and physical examination are important in determining the etiology of Acute Kidney Injury. The history can identify nephrotoxic medications or a systemic illness contributing to impaired renal function. The physical examination should focus on evaluating intravascular volume status. Skin rashes may indicate an underlying condition (e.g., systemic lupus erythematosus, atheroembolism/vasculitis) or exposure (e.g., drug rash suggesting acute interstitial necrosis) leading to acute kidney injury. The diagnosis of Acute Kidney Injury is traditionally based on a rise in serum creatinine and/or a fall in urine output. The laboratory assessment includes the measurement of serum creatinine level, urinalysis, renal biopsy, urine electrolytes, and others.
Further details related to diagnosis are provided in the report…
Acute Kidney Injury Treatment
The therapeutic strategies for Acute Kidney Injury based on the KDIGO guidelines and bundles of care are limited and mostly supportive. The clinical approach should begin with hemodynamic stabilization, the early identification of Acute Kidney Injury complications, its cause, and its treatment. Hemodynamic stabilization is of critical significance because autoregulation mechanisms are impaired in Acute Kidney Injury. The treatment for Acute Kidney Injury depends on the cause of the condition. Most people need to stay in the hospital during treatment and until the recovery of the kidneys. Some possible treatments apart from temporary hemodialysis include medicines to control the amounts of vitamins and minerals in the blood, and treatments to keep the right amount of fluid in the blood. There is no approved treatment for Acute Kidney Injury, the current treatment practices use conventional therapies (vasopressor, diuretics, statins, and others) and Renal Replacement Therapies (RRT). The acute renal failure pipeline drugs market is rapidly expanding with innovative treatments showing promising therapeutic potential.
.jpg)
Acute Kidney Injury Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of Acute Kidney Injury in Hospitalized Patients, Mortality Adjusted Incident Population of Acute Kidney Injury in Hospitalized Patients, Stage-specific Incident Population of Acute Kidney Injury, and, Age-specific Incident Population of Acute Kidney Injury in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
- The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the 7MM comprised 14.6 million cases in 2022 and are projected to increase during the forecast period.
- The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the United States were approximately 5.7 in 2022.
- The US contributed to the largest incident population of Acute Kidney Injury, accounting for ~ 39% in the 7MM in 2022.
- Among EU4 and the UK, Germany accounted for the highest number of Acute Kidney Injury cases, followed by France, whereas Spain accounted for the lowest cases in 2022.
- The stage-specific cases of Acute Kidney Injury include Stage I, Stage II, and, Stage III. Out of which maximum cases were reported in stage I Acute Kidney Injury followed by stage II and Stage III.
Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Acute Kidney Injury Prevalence
Acute Kidney Injury Drug Chapters
The drug chapter segment of the Acute Kidney Injury therapeutics market report encloses a detailed analysis of Acute Kidney Injury emerging (Phase-III and Phase II and Phase I/II) Acute Kidney Injury pipeline drugs analysis. It also helps to understand the Acute Kidney Injury clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest Acute Kidney Injury news and press releases.
Acute Kidney Injury Emerging Drugs
- RBT-1: Renibus Therapeutics
RBT-1 by Renibus Therapeutics is an investigational drug that upregulates anti-inflammatory, antioxidant, and iron-scavenging pathways, activating a cytoprotective preconditioning response to reduce the risk of postoperative complications and improve patient outcomes following cardiothoracic surgery. The RBT-1-mediated pharmacologic preconditioning is thought to induce broad organ protection, thereby mitigating the risks of postoperative complications and improving both short- and long-term outcomes. In July 2023, Renibus Therapeutics announced that the US FDA granted Breakthrough Therapy Designation to RBT-1 for the reduction in risk of postoperative complications in patients undergoing cardiothoracic surgery and confirmed its alignment with the company’s planned Phase III pivotal trial. In October 2023, Renibus Therapeutics announced that the first patient had been dosed in the pivotal Phase III PROTECT trial of RBT-1. Top-line results are expected in mid-2025. NDA filing is anticipated by early 2026.
- OCE-205: Ocelot Bio
Ocelot Bio’s lead asset, OCE-205, is a therapeutic peptide with a differentiated mechanism of action that has the potential to improve outcomes for patients with complications of end-stage liver disease (ESLD). OCE-205’s innovation emanates from its design as a mixed agonist-antagonist peptide selective for the vasopressin 1a (V1a) receptor with no vasopressin 2 (v2) receptor activity at drug concentrations well above those used in treating ESLD. In August 2022, Ocelot Bio announced that the US FDA granted ODD to OCE-205 for the treatment of hepatorenal syndrome. Ocelot Bio has completed the enrolment of patients in a Phase II clinical trial of OCE-205 in hepatorenal syndrome with acute kidney injury (HRS-Acute Kidney Injury).
Note: Detailed emerging therapies assessment will be provided in the final report.
Acute Kidney Injury Drugs Market Insights
Patients suffering from Acute Kidney Injury are often prescribed diuretics, with loop diuretics being the most commonly recommended class of dialectics. Furosemide, which is a potent loop diuretic, is frequently used in different stages of Acute Kidney Injury since it offers the possibility of eliminating large amounts of electrolytes and water as long as the kidneys are capable of filtration.
.jpg)
Acute Kidney Injury Market Outlook
A robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of the Acute Kidney Injury therapeutics market. Additionally, the Acute Kidney Injury pipeline is also expected to change the current dynamics of the market, which presently comprises biologics and molecules with new mechanisms of action. Currently, there are no targeted pharmacotherapies approved for the treatment of Acute Kidney Injury. At present, the therapeutic market size of Acute Kidney Injury is mainly dominated by the use of RRT and off-label drugs, which include various classes such as ACE inhibitors, ARBs, Diuretics, and NSAIDs.
Various comorbidities like cardiovascular disease, hypertension, diabetes mellitus, pre-existing CKD, renal recovery, and others increase the risk of Acute Kidney Injury in these patients. As mentioned earlier, the current market of Acute Kidney Injury is majorly dependent on RRT and conventional therapies like NSAIDs, ACE inhibitors, ARBs, diuretics, etc. However, this might change in the future, as there are various emerging therapies in the pipeline targeting Acute Kidney Injury caused by comorbidities like sepsis, cardiac surgery, delayed graft function, and others. The pipeline of Acute Kidney Injury possesses novel candidates targeting HRS-Acute Kidney Injury, post cardiac surgery, and Acute Kidney Injury due to sepsis are diversifying the treatment options that can reduce the current unmet need in Acute Kidney Injury. The current emerging pipeline consists of key players including Renibus Therapeutics (RBT-1), Ocelot Bio (OCE-205), AM-Pharma (Ilofotase alfa), Guard Therapeutics (RMC-035), and others who are developing their products to address the patient population and reduce mortality rates in hospital settings. Overall, the Acute Kidney Injury therapeutics market is further expected to increase in the forecast period (2024–2034).
- The total Acute Kidney Injury Market Size in the 7MM was ~USD 6,230 million in 2022 and is projected to grow during the forecast period (2024-2034).
- According to the estimates, the highest Acute Kidney Injury Market Size is from the United States, in 2022 and is anticipated to grow at a CAGR of 4.1%.
- Among EU4 and the UK, Germany has the maximum revenue share in 2022 while Spain has the lowest Acute Kidney Injury market share.
- The Acute Kidney Injury Market Size in Japan was USD 35 million in 2022 which is expected to rise during the forecast period (2024-2034).
Acute Kidney Injury Drugs Uptake
This section focuses on the rate of uptake of the potential Acute Kidney Injury drugs expected to be launched in the market during the study period 2020-2034. The analysis covers Acute Kidney Injury market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- AM-Pharma’s therapeutic candidate is a proprietary recombinant human Alkaline Phosphatase (Ilofotase alfa) constructed from two naturally occurring human isoforms of the AP enzyme.
Acute Kidney Injury Pipeline Development Activities
The Acute Kidney Injury therapeutics market report provides insights into different Acute Kidney Injury clincial trials within Phase III, Phase II, and Phase I/II stage. It also analyzes key Acute Kidney Injury Companies involved in developing targeted therapeutics.
Pipeline Development Activities
The Acute Kidney Injury therapeutics market report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for Acute Kidney Injury emerging therapies.
Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Acute Kidney Injury Treatment Drugs
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, Professor and Vice Chair Department of Critical Care Medicine and Director, Center for Critical Care Nephrology, PhD, and others. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Acute Kidney Injury market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Acute Kidney Injury unmet needs.
Delveinsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Center for Kidney Diseases, Department of Rheumatology, Department of Nephrology, etc., were contacted. Their opinion helps understand and validate Acute Kidney Injury epidemiology and market trends.
Acute Kidney Injury Therapeutics Market: Qualitative Analysis
We perform Qualitative and Acute Kidney Injury Drugs Market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving Acute Kidney Injury treatment market landscape. The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.
In efficacy, the trial’s primary and secondary outcome measures are evaluated. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.
Acute Kidney Injury Market Access and Reimbursement
In January 2017, the Centers for Medicare and Medicaid Services published that end-stage renal disease (ESRD) facilities will be able to furnish dialysis services to Acute Kidney Injury patients. The provision provides Medicare coverage and payment to both hospital-based and freestanding ESRD facilities for renal dialysis services furnished to beneficiaries with Acute Kidney Injury. Medicare will pay ESRD facilities for dialysis treatment using the ESRD Prospective Payment System (PPS) base rate adjusted by the wage index. In addition to the dialysis treatment, the ESRD PPS base rate pays ESRD facilities for the items and services that are renal dialysis services, and there will be no separate payment for those services. Specifically, this includes renal dialysis drugs, biologicals, laboratory services, and supplies that are included in the ESRD PPS base rate when furnished by an ESRD facility to an individual with Acute Kidney Injury.
Acute Kidney Injury Therapeutics Market Report Scope
- The Acute Kidney Injury therapeutics market report covers a descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the Acute Kidney Injury epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Acute Kidney Injury is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Acute Kidney Injury treatment market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The Acute Kidney Injury therapeutics market report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acute Kidney Injury drugs market.
Acute Kidney Injury Therapeutics Market Report Insights
- Acute Kidney Injury Report Insights
- Acute Kidney Injury Patient Population
- Acute Kidney Injury Therapeutic Approaches
- Acute Kidney Injury Pipeline Drugs Analysis
- Acute Kidney Injury Market Size and Trends
- Acute Kidney Injury Drugs Market Opportunities
- Impact of Upcoming Acute Kidney Injury Therapies
Acute Kidney Injury Treatment Market Report Key Strengths
- 10 Years Acute Kidney Injury Market Forecast
- 7MM Coverage
- Acute Kidney Injury Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Acute Kidney Injury Drugs Market
- Acute Kidney Injury Drugs Uptake
Acute Kidney Injury Therapeutics Market Report Assessment
- Current Acute Kidney Injury Treatment Market Practices
- Acute Kidney Injury Unmet Needs
- Acute Kidney Injury Pipeline Drugs Profiles
- Acute Kidney Injury Drugs Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
- Acute Kidney Injury Market Drivers
- Acute Kidney Injury Market Barriers
FAQs
- What was the Acute Kidney Injury drugs market share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Acute Kidney Injury market size as well as market size by therapies across the 7MM during the study period (2020–2034)?
- What are the key findings about the market across the 7MM and which country will have the largest Acute Kidney Injury market size during the study period (2020–2034)?
- At what CAGR, the Acute Kidney Injury drugs market is expected to grow at the 7MM level during the study period (2020–2034)?
- What would be the Acute Kidney Injury market outlook across the 7MM during the study period (2020–2034)?
- What would be the Acute Kidney Injury market growth till 2034 and what will be the resultant market size in the year 2034?
- What are the disease risk, burden, and unmet needs of Acute Kidney Injury?
- What is the historical Acute Kidney Injury patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- What would be the forecasted patient pool of Acute Kidney Injury at the 7MM level?
- What will be the growth opportunities across the 7MM concerning the patient population of Acute Kidney Injury?
- Out of the above-mentioned countries, which country would have the highest incident population of Acute Kidney Injury during the study period (2020–2034)?
- At what CAGR the population is expected to grow across the 7MM during the study period (2020–2034)?
- How many companies are developing therapies for the treatment of Acute Kidney Injury?
- How many emerging therapies are in the mid-stage and late stage of development for the treatment of Acute Kidney Injury?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, and licensing activities related to the Acute Kidney Injury therapies?
- What are the recent novel therapies, targets, Acute Kidney Injury Mechanisms of Action, and technologies developed to overcome the limitations of existing therapies?
- What are the Acute Kidney Injury clinical trials going on and their status?
- What are the key designations that have been granted for the Acute Kidney Injury emerging therapies?
- What are the 7MM historical and forecasted Acute Kidney Injury Drugs Market?
Reasons to Buy
- The Acute Kidney Injury therapeutics market report will help in developing business strategies by understanding trends shaping and driving the Acute Kidney Injury.
- To understand the future market competition in the Acute Kidney Injury drugs market and Insightful review of the SWOT analysis of Acute Kidney Injury.
- Organize sales and marketing efforts by identifying the best opportunities for Acute Kidney Injury in the US, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
- Identification of strong upcoming players in the Acute Kidney Injury drugs market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Acute Kidney Injury drugs market.
- To understand the future market competition in the Acute Kidney Injury drugs market.
Get detailed insights on related blogs below:
.png&w=48&q=75){kind=small}